Today is certainly a better start. It seems that the sector is trading to a certain extent on macro issues with the DB concerns leading to risk on versus risk off action. The sector will always be a victim to large risk off moves, so if the DB situation resolves I would not be surprised […]
June 3 Biotech Update
Not much in terms of news to end the week as we head into ASCO. The jobs report may make this a macro day sell off (although if you dig into the jobs report the big miss seems to be driven entirely by the Verizon strike, so when that ends this should completely reverse). In […]
May 5 Biotech Update
We saw more of the same selling yesterday. It was across the market but it certainly felt like the sector led to the downside and failed to bounce when the market came back a little. Today is off to a better start but at this point I am not sure anyone thinks it will stick […]
October 26 Biotech Update
I really thought the week would start with more of a bang but it seems much more like a whimper. Sure we had more VRX news/speculation but we really did not learn anything that new. The bears are bears and the bulls are hiding and most have no clue what exactly is going on. The […]
September 11 Biotech Update
Macro seems to be slowly fading into the background but note that I said slowly as it will likely take more time and it should remain meaningful in the short term. Of course, fading into the background does not mean all is clear for the next move higher as I read the market as simply […]
August 12 Biotech Update
Essentially more of the same yesterday and into the morning today. At the very least, I think we are probably close to a bounce and would not be surprised to see a gap lower this morning and then a rally into the green by the end of the day. It is amazing that the market […]
April 28 Biotech Update
So it ended up being a bad start to the week with a significant drop straight down to support with follow through early this morning. The sector seemed to find some support at support levels yesterday but it felt tenuous. Keep in mind that we have yet to have the big scary correction this year […]
April 21 Biotech Update
A lot of news to cover and I want to get to it all, so maybe a little less detail and more topics today and I will circle back to the ideas over the next couple of days. In general, the sector is doing well with the deal flow news but I will talk more […]
April 10 Biotech Update
A good opening to the sector and large caps but the move was almost immediately faded (especially the large caps). Yesterday ended better than the past, so perhaps the sector can recover and regain the lost ground but I still worry about this pattern of strong openings that are continually sold throughout the day. It […]
Chimera Research Group Catalyst Summary for March 2015
At the end of each month Chimera Research Group provides you with a monthly summary of TEN notable catalysts/events that have occurred during the past month. MARCH 2015: 1) Bristol-Myers Squibb Company (NYSE:BMY) announced that the FDA approved the expanded use of Opdivo to treat patients with advanced squamous non-small cell lung cancer (NSCLC). Approval came just over two […]
March 23 Biotech Update
A weak start to the week but it is also a continuation from the weak ending of last week. Everyone is waiting for a pullback. The bulls expect a moderate pullback to consolidate the move, the bears expect a more significant move to purge a lot of the excess valuation, and the bubble callers are […]
December 22 Biotech Update
It was a weak start to the sector and I suspect that may be a popular start to these notes as the sector seems to have lost some control of pricing power. I am going to spend today talking about the ABBV/ESRX deal as it has significant implications not over for the hep-C market but […]
July 30 Biotech Update
The sector and market rallied nicely on the GDP but I am still not convinced that we have an all clear. It was especially disconcerting how quickly the market gave back a lot of the post GDP print gains. Of course, there are still values out there and no reason to sell and run for […]
July 14 Biotech Update
It was a mixed day in the market as the broader market seemed good but biotechs seemed more mixed. I am not sure these is much to make out of it as the key over the next couple of weeks will be earnings (at least for the larger biotechs) and then once we get through […]
July 2 Biotech Update
A tough end to USA soccer in the World Cup but another good morning for biotech stocks. I have some follow up discussion from earlier this week as there is not a ton of new news this morning. I suspect that will be the case as we get closer to the long weekend (but we, […]
Catalyst Watch – Vol. 2, Edition 21 (6/26/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates MNKD: PDUFA […]
Catalyst Watch – Vol. 2, Edition 20 (6/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates No updates […]
Catalyst Watch – Vol. 2, Edition 19 (6/13/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates CNAT: Holding […]
Catalyst Watch – Vol. 2, Edition 18 (6/3/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates ETRM: As […]
Catalyst Watch – Vol. 2, Edition 17 (5/29/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates DRTX: Dalvance […]
